Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent or Treat Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation

NCT07254793 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT07254793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07254793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent or Treat Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
University of Arizona
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 1, 2030
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia, acute myeloid leukemia, acute undifferentiated leukemia (aul), chronic myeloid leukemia, myelodysplastic syndrome, non-hodgkin lymphoma